Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure

Previous studies suggested increased mortality in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute‐on‐chronic liver failure (ACLF).

[1]  Douglas A. Simonetto,et al.  Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. , 2021, The New England journal of medicine.

[2]  J. Clària,et al.  Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure , 2020, Cells.

[3]  Douglas A. Simonetto,et al.  Hepatorenal syndrome: pathophysiology, diagnosis, and management , 2020, BMJ.

[4]  R. Moreau,et al.  Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment , 2020, JHEP reports : innovation in hepatology.

[5]  N. Mahmud,et al.  Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure , 2020, Hepatology.

[6]  F. Wong.  Latest Treatment of Acute Kidney Injury in Cirrhosis , 2020, Current Treatment Options in Gastroenterology.

[7]  M. Israelsen,et al.  Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomised controlled trial. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[8]  F. Nevens,et al.  Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  T. Reiberger.  When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome? , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  K. Reddy,et al.  Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time? , 2018, Hepatology.

[11]  P. Kamath,et al.  Hepatorenal syndrome , 2018, Nature Reviews Disease Primers.

[12]  M. Murad,et al.  Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. , 2017, The lancet. Gastroenterology & hepatology.

[13]  Richard Moreau,et al.  Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.

[14]  D. Ganger,et al.  Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. , 2016, Gastroenterology.

[15]  H. Rabb,et al.  Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets. , 2016, Kidney international.

[16]  W. Druml,et al.  Systemic consequences of acute kidney injury , 2014, Current opinion in critical care.

[17]  J. Kellum,et al.  A Unified Theory of Sepsis-Induced Acute Kidney Injury: Inflammation, Microcirculatory Dysfunction, Bioenergetics, and the Tubular Cell Adaptation to Injury , 2014, Shock.

[18]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[19]  E. Tsianos,et al.  Differential Effects of Terlipressin on Pulmonary and Systemic Hemodynamics in Patients With Cirrhosis and Pulmonary Hypertension , 2012, Angiology.

[20]  J. Dasta,et al.  Terlipressin in Hepatorenal Syndrome , 2011, The Annals of pharmacotherapy.

[21]  A. Krag,et al.  Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis , 2010, European journal of gastroenterology & hepatology.

[22]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[23]  V. Arroyo,et al.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. , 2008, Gastroenterology.

[24]  Vicente Arroyo,et al.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis , 2007, Postgraduate Medical Journal.

[25]  F. Durand,et al.  Hepatorenal syndrome , 1996, Digestive Diseases and Sciences.

[26]  Gyeong a Kim,et al.  Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study , 2008 .

[27]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .